Post Private Sale
An in-depth look at the FDA’s refurb docket
re: A liability imbalance
August 05, 2016 07:32
Interesting observation, Brian. In general, we've certainly heard a lot of frustration from HTMs regarding inadequate access to OEM information.
Maybe the Carestream approach, despite its limitations, is a step in the right direction?
One nice thing about this docket is that it allows those types of concerns and insights to be heard by a larger audience than just your peers. Nobody we've spoken to -- OEM or third-party -- seems totally satisfied with the current state of things.
Log in to Reply
You must be logged in to comment.